SCHEMBL5830664

SCHEMBL5830664

O=C(Cc1nsc(NS(=O)(=O)c2ccc(-c3ccccc3)cc2)n1)N1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
USP36 Q9P275 1/20 0.45
PTGS2 P35354 1/20 0.43
GAA P10253 1/20 0.42
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NAAA Q02083 1/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 1/20 0.41
F2 P00734 1/20 0.41
PRSS1 P07477 1/20 0.41
LMNA P02545 2/20 0.40
KDM1A O60341 1/20 0.40
SCN9A Q15858 1/20 0.40
MMP2 P08253 1/20 0.40
MMP13 P45452 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5832016 0.91 USP36 (0.44) USP36PTGS2GAAPOLBALDH1A1
SCHEMBL5831705 0.90 MAPT (0.52) USP36PTGS2GAAPOLBSMN1; SMN2
SCHEMBL7064422 0.85 NAAA (0.43) PTGS2SMN1; SMN2NAAAALDH1A1HPGD
SCHEMBL5831153 0.84 HPGD (0.53) GAAPOLBALDH1A1HPGDLMNA
SCHEMBL3621607 0.82 ALDH1A1 (0.53) POLBALDH1A1F2KDM1A
SCHEMBL5831268 0.81 ATM (0.50) GAASMN1; SMN2ALDH1A1HPGDHSD17B10
SCHEMBL5830800 0.81 HSD11B1 (0.51) GAAPOLBSMN1; SMN2ALDH1A1LMNA
SCHEMBL5830740 0.81 HSD11B1 (0.46) GAAALDH1A1HSD17B10LMNA
SCHEMBL3250348 0.80 HSD11B1 (0.52) PTGS2GAAPOLBSMN1; SMN2NAAA
SCHEMBL5831017 0.79 SMN1; SMN2 (0.48) GAAPOLBSMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004113310-A1 USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 USP36 3719/4885PTGS2 1198/4885GAA 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.